Screener
Corcept Therapeutics CORT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $14,910 | $40,444 |
| Accrued research and development expenses | 21,628 | 33,954 |
| Accrued and other liabilities | 115,347 | 90,603 |
| Short-term operating lease liability | 1,917 | 1,084 |
| Total current liabilities | 153,802 | 166,085 |
| Long-term operating lease liability | 7,504 | 5,023 |
| Long-term accrued government rebates | 6,132 | 2,562 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's accrued expenses?
- Corcept Therapeutics (CORT) reported accrued expenses of $115.35M in Q2 2026.
- How has Corcept Therapeutics's accrued expenses changed year-over-year?
- Corcept Therapeutics's accrued expenses increased by 26.7% year-over-year, from $91.07M to $115.35M.
- What is the long-term trend for Corcept Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Corcept Therapeutics's accrued expenses has grown at a 33.7% compound annual growth rate (CAGR), from $21.19M to $90.6M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Corcept Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude